2023
Comparative effectiveness and cost-effectiveness of cardioprotective glucose-lowering therapies for type 2 diabetes in Brazil: a Bayesian network model
Nogueira A, Barreto J, Moura F, Luchiari B, Abuhab A, Bonilha I, Nadruz W, Gaziano J, Gaziano T, de Carvalho L, Sposito A. Comparative effectiveness and cost-effectiveness of cardioprotective glucose-lowering therapies for type 2 diabetes in Brazil: a Bayesian network model. Health Economics Review 2023, 13: 50. PMID: 37878108, PMCID: PMC10599033, DOI: 10.1186/s13561-023-00466-3.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioGlucose-lowering therapyType 2 diabetesNetwork meta-analysisSecondary preventionPrevalence of type 2 diabetesBrazilian public health systemRisk of cardiovascular outcomesPublic health systemCost-effectiveReduced relative riskNon-fatal cardiovascular eventsContext of primary preventionConclusionsIn BrazilClasses of glucose-lowering therapiesHealth systemManagement of T2DMGLP-1aCost-effectiveness modelStandard carePrimary preventionCost-effectiveness ratioRelative riskEvidence-basedInternational dollars
2022
Abstract 14830: Comparative Cost-Effectiveness of Cardioprotective Glucose-Lowering Therapies for Type 2 Diabetes in a Middle-Income Country: A Bayesian Network Model
Carvalho L, Nogueira A, Antunes J, Moura F, Luchiari B, Bonilha I, Nadruz W, Gaziano M, Gaziano T, Sposito A. Abstract 14830: Comparative Cost-Effectiveness of Cardioprotective Glucose-Lowering Therapies for Type 2 Diabetes in a Middle-Income Country: A Bayesian Network Model. Circulation 2022, 146: a14830-a14830. DOI: 10.1161/circ.146.suppl_1.14830.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioGLP-1RAMiddle-income countriesType 2 diabetesCardiovascular eventsRisk of non-fatal cardiovascular eventsFollow-up >Pre-specified endpointsCohort of T2D patientsNon-fatal cardiovascular eventsGlucose-lowering therapySecondary prevention cohortAdverse cardiovascular eventsAnti-diabetic therapyRandomized clinical trialsCost-effectiveness ratioBrazilian public health systemDouble-blindGLP1-RAPublic health systemPrevention cohortProspective cohortT2D subjectsHeart failureT2D patients